Allotment of Securities

20 August 2026 BSE Limited National Stock Exchange of India Limited Corporate Relationship Department The Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, Plot No. C/1, G Block, Dalal Street, Bandra – Kurla Complex, Bandra (East) Mumbai – 400 001 Mumbai – 400 051 BSE Scrip Code: 543308 NSE Symbol: KIMS Dear Madam / Sir, Subject: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - allotment of 77,02,182 (seventy- seven lakh two thousand one hundred and eighty-two) warrants on a preferential basis by Krishna Institute of Medical Sciences Limited (“Company”) to Dr. Abhinay Bollineni (Promoter), Mr. Adwik Bollineni (Promoter) and Bharas Ventures LLP (a Promoter Group entity). Further to the intimation dated 13 June 2026 in relation to the approval of the board of directors of the Company (“Board”) for the issuance and allotment of 77,02,182 (seventy-seven lakh two thousand one hundred and eighty-two) warrants on a preferential basis by the Company to Dr. Abhinay Bollineni (Promoter), Mr. Adwik Bollineni (Promoter) and Bharas Ventures LLP (a Promoter Group entity) (“Allottees”) (“Preferential Issue”), the intimation dated 11 July 2026 in relation to the details of the voting results of the extraordinary general meeting of the Company held on 9 July 2026 (wherein the shareholders of the Company approved the Preferential Issue with requisite majority) and the in-principle approval in relation to the Preferential Issue provided respectively by the BSE Limited (by way of their letter bearing reference number LOD/PREF/KS/FIP/633/2026-27) and the National Stock Exchange of India Limited (by way of their letter bearing reference number NSE/LIST/55834), we hereby inform that the Company has received in aggregate Rs. 1,499,999,944.50 (Rupees One hundred forty-nine crore ninety-nine lakh ninety-nine thousand nine hundred forty-four rupees and fifty paise) from the Allottees for the warrant subscription, which is equivalent to 25% of the issue price of the said Warrants. Further we wish to inform you that upon receipt of 25 % of the issue price of the said Warrants (i.e., warrant subscription money), the Finance and Investment Committee of the Board has by way of a resolution passed by circulation on 19 August 2026 (Wednesday) at 18:45 hrs (IST), approved the allotment of 77,02,182 (seventy-seven lakh two thousand one hundred and eighty-two) warrants on a preferential basis by the Company to the Allottees (namely Dr. Abhinay Bollineni (Promoter), Mr. Adwik Bollineni (Promoter) and Bharas Ventures LLP (a Promoter Group entity)), in dematerialized form, as set out in the table below: Sr. Name of the Allottees Category Number Subscription Pre- Post-Preferential No. @ of Amount received Preferential Issue Warrants (25% of Issue shareholding allotted Warrants Issue shareholding and % Price) (INR) and % (assuming 100% (assuming conversion of 100% Warrants) conversion of Warrants) 1. Dr. Abhinay Bollineni Promoter 32,09,242 624,999,879.50/- 2,36,495 34,45,737 (0.06%) (0.81%) 2. Mr. Adwik Bollineni Promoter 32,09,242 624,999,879.50/- 40,640 32,49,882 (0.01%) (0.76%) 3. Bharas Ventures LLP, a Promoter 12,83,698 250,000,185.50/- NIL 12,83,698 limited liability Group (0.30%) partnership with Dr. Bhaskara Rao Bollineni (being Promoter of the Company) and Ms. Rajyasri Bollineni (being Promoter of the Company) having made the entire capital contribution of Bharas Ventures LLP Total - 77,02,182 1,499,999,944.50/- - - Category Pre-Preferential Issue Post-Preferential Issue shareholding and %* shareholding and %& Promoter and Promoter Group 32.50% 33.71% @ Dr. Abhinay Bollineni and Mr. Adwik Bollineni prior to the completion of the Preferential Issue are Promoters of the Company and will continue to remain Promoters of the Company post the completion of the Preferential Issue. Similarly, Bharas Ventures LLP prior to the completion of the Preferential Issue is a part of the Promoter Group of the Company and will continue to remain part of the Promoter Group of the Company post the completion of the Preferential Issue. * Given the Proposed Allotees form part of the promoter and promoter group of the Company, we have disclosed the pre- preferential issue shareholding and % for the promoter and promoter group of the Company, as publicly available, basis the quarterly shareholding pattern for the quarter ended 30 June 2026. & Given the Allotees form part of the promoter and promoter group of the Company, we have disclosed the post-preferential issue shareholding and % for the promoter and promoter group of the Company, after having assumed that all Warrants, at a conversion ratio of 1:1, will be converted into equity shares by the Allottees within the timelines prescribed under the SEBI ICDR Regulations.. The Warrants shall be convertible into equity shares of the Company within a period of 18 (Eighteen) months from the date of allotment of the Warrants. The balance i.e., 75% of the issue price of the Warrants shall be payable by the Warrant holders at the time of exercise of the right attached to the Warrants to convert the Warrants and subscribe to equity shares of the Company. (cid:0)(cid:3) (cid:0)(cid:3) (cid:0)(cid:3)(cid:0)I(cid:0)(cid:3)(cid:0)Q(cid:0)R(cid:0)U(cid:0)(cid:3)(cid:0)W(cid:0)K(cid:0)D(cid:0)K(cid:0)H(cid:0)Q(cid:0)J(cid:0)H(cid:0)(cid:3)(cid:0)Q(cid:0)G(cid:0)W(cid:0)V(cid:0)W(cid:0)N(cid:0)V(cid:0)(cid:3)(cid:0)U(cid:0)P(cid:0)(cid:3)(cid:0)O(cid:0)G(cid:0)S(cid:0)L(cid:0)(cid:3)(cid:0)\(cid:0)X(cid:0)G(cid:0)(cid:3)(cid:0)W(cid:0)S(cid:0)O(cid:0)K(cid:0)(cid:3)(cid:0)(cid:3)(cid:0)((cid:0)W(cid:0)[(cid:0)F(cid:0)W(cid:0)L(cid:0)(cid:3)(cid:0)Q(cid:0)(cid:3)(cid:0)U(cid:0)W(cid:0)L(cid:0)R(cid:0)(cid:3)(cid:0)P(cid:0)R(cid:0)W(cid:0)D(cid:0)K(cid:0)H(cid:0)R(cid:0)L(cid:0)D(cid:0)W(cid:0)Q(cid:0)J(cid:0)D(cid:0)Q(cid:0)H(cid:0)K(cid:0)H(cid:0)S(cid:0)(cid:3)(cid:0)6(cid:0)W(cid:0)H(cid:0)R(cid:0)F(cid:0)D(cid:0)V(cid:0)N(cid:0)H(cid:0)L(cid:0)&(cid:0)F(cid:0)J(cid:0)D(cid:0)D(cid:0)Q(cid:0)(cid:3)(cid:0)D(cid:0)7(cid:0)H(cid:0)N(cid:0)R(cid:0)(cid:3) (cid:0)T(cid:0)W(cid:0)(cid:3)(cid:0)X(cid:0)L(cid:0)H(cid:0)\(cid:0)U(cid:0)H(cid:0)K(cid:0)V(cid:0)(cid:3)(cid:0)V(cid:0)D(cid:0)W(cid:0)R(cid:0)(cid:3)(cid:0)(cid:3)(cid:0)E(cid:0)H(cid:0)O(cid:0)O(cid:0)R(cid:0)W(cid:0)(cid:3)(cid:0)D(cid:0)W(cid:0)H(cid:0)G(cid:0)(cid:3)(cid:0)X(cid:0)S(cid:0)R(cid:0)Q(cid:0)(cid:3)(cid:0)W(cid:0)K(cid:0)U(cid:0)F(cid:0)L(cid:0)H(cid:0)H(cid:0)(cid:3)(cid:0)V(cid:0)[(cid:0)H(cid:0)R(cid:0)I(cid:0)H(cid:0)(cid:3)(cid:0)(cid:3)(cid:0)W(cid:0)K(cid:0)H(cid:0)W(cid:0)(cid:3)(cid:0)U(cid:0)L(cid:0)J(cid:0)K(cid:0)(cid:3)(cid:0)R(cid:0)Q(cid:0)R(cid:0)I(cid:0)L(cid:0)(cid:3)(cid:0)R(cid:0)Q(cid:0)H(cid:0)U(cid:0)V(cid:0)Y(cid:0)F(cid:0)R(cid:0)I(cid:0)(cid:3)(cid:0)W(cid:0)K(cid:0)H(cid:0)(cid:3)(cid:0)(cid:3)(cid:0)D(cid:0)W(cid:0)V(cid:0)U(cid:0)U(cid:0):(cid:0)D(cid:0)Q(cid:0)L(cid:0)Q(cid:0)W(cid:0)R(cid:0)(cid:3)(cid:0)(cid:3)(cid:0)T(cid:0)W(cid:0)X(cid:0)L(cid:0)\(cid:0)H (cid:0)L(cid:0)O(cid:0)Z(cid:0)(cid:17)(cid:0)(cid:3)(cid:0)O(cid:0)E(cid:0)O(cid:0)(cid:3)(cid:0)Z(cid:0)W(cid:0)D(cid:0)K(cid:0)(cid:3)(cid:0)D(cid:0)Q(cid:0)S(cid:0)S(cid:0)(cid:3)(cid:0)F(cid:0)R(cid:0)U(cid:0)G(cid:0)H(cid:0)(cid:3)(cid:0)L(cid:0)Q(cid:0)F(cid:0)D(cid:0)H(cid:0)(cid:3)(cid:0)O(cid:0)F(cid:0)H(cid:0)(cid:15)(cid:0)L(cid:0)D(cid:0)W(cid:0)G(cid:0)D(cid:0)O(cid:0)(cid:3)(cid:0)D(cid:0)F(cid:0)(cid:3)(cid:0)(cid:3)(cid:0)U(cid:0)U(cid:0)R(cid:0)W(cid:0)V(cid:0)R(cid:0)S(cid:0)H(cid:0)H(cid:0)E(cid:0)W(cid:0)K(cid:0)H(cid:0)(cid:3)(cid:0)S(cid:0)K(cid:0)D(cid:0)H(cid:0)R(cid:0)V(cid:0)V(cid:0)\(cid:0)V (cid:0)(cid:3) (cid:0)(cid:3)(cid:0)6(cid:0)L(cid:0)Q(cid:0)F(cid:0)H(cid:0)(cid:3)(cid:0)W(cid:0)K(cid:0)H(cid:0)Q(cid:0)R(cid:0)\(cid:0)(cid:3)(cid:0)S(cid:0)&(cid:0)P(cid:0)D(cid:0)D(cid:0)(cid:3)(cid:0)K(cid:0)V(cid:0)O(cid:0)O(cid:0)R(cid:0)W(cid:0)(cid:3)(cid:0)D(cid:0)W(cid:0)H(ci [Showing first 8,000 characters — download PDF for full document]